Roivant Sciencesの空売り状況は、投資家がRoivant Sciencesの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Roivant Sciences (NASDAQ:ROIV) 株価情報, 空売り情報

Roivant Sciences

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

Roivant Sciences Ltd

ROIVANT SCIENCES LTD WT EXP

UBS analyst Kunal Madhukar maintains Bumble (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMBL#NASDAQ">BMBL</a>) with a Neutral and raises the price target from $5 to $6.

News

Price Target

Analyst Ratings

BMBL

UBS Maintains Neutral on Bumble, Raises Price Target to $6

Cosmos Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COSM#NASDAQ">COSM</a>) reported quarterly losses of $(0.03) per share. This is a 72.73 percent increase over losses of $(0.11) per share from the same period last year. The company reported $13.71 million in sales this quarter. This is a 5.98 percent decrease over sales of $14.58 million the same period last year.

Earnings

COSM

Cosmos Health Q1 EPS $(0.03) Up From $(0.11) YoY, Sales $13.71M Down From $14.58M YoY

Applied Materials, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) will release its second-quarter financial results after the <a href="https://www.benzinga.com/quote/AMAT/earnings">closing bell on Thursday, May 15.</a>
Analysts expect the Santa Clara, California-based company to report quarterly earnings at $2.31 per share, up from $2.09 per share in the year-ago period. Applied Materials projects quarterly revenue of $7.12 billion, compared to $6.65 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On April 22, Barclays analyst Tom O&#8217;Malley maintained the stock with an Equal-Weight rating and lowered the price target from $190 to $160.
With the recent buzz around Applied Materials, some investors may be eyeing potential gains from the company's dividends. Currently, Applied Materials offers an annual dividend yield of 1.06%, which is a quarterly dividend amount of 46 cents per share ($1.84 a year).
To figure out how to earn $500 monthly from Applied Materials, we start with a yearly target of $6,000 ($500 x 12 months).
Next, we take this amount and divide it by Applied Materials' $1.84 dividend: $6,000 / $1.84 = 3,261 shares.
So, an investor would need to own approximately $567,871 worth of Applied Materials, or 3,261 shares to generate a monthly dividend income of $500.
Assuming a more conservative goal of $100 monthly ($1,200 annually), we do the same calculation: $1,200 / $1.84 = 652 shares, or $113,539 to generate a monthly dividend income of $100.
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
The dividend yield is calculated by dividing the annual dividend payment by the current stock price. As the stock price changes, the dividend yield will also change.
For example, if a stock pays an annual dividend of $2 and its current price is $50, its dividend yield would be 4%. However, if the stock price increases to $60, the dividend yield would decrease to 3.33% ($2/$60).
Conversely, if the stock price decreases to $40, the dividend yield would increase to 5% ($2/$40).
Further, the dividend payment itself can also change over time, which can also impact the dividend yield. If a company increases its dividend payment, the dividend yield will increase even if the stock price remains the same. Similarly, if a company decreases its dividend payment, the dividend yield will decrease.
AMAT Price Action: Shares of Applied Materials gained by 0.6% to close at $174.14 on Wednesday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More:<a href="https://www.benzinga.com/25/05/45405004/jim-cramer-sofi-goes-to-new-highs-recommends-not-buying-this-health-care-stock"> </a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45405004/jim-cramer-sofi-goes-to-new-highs-recommends-not-buying-this-health-care-stock">Jim Cramer: SoFi Goes To &#8216;New Highs,&#8217; Recommends Not Buying This Health Care Stock</a></li>
</ul>
Image: Shutterstock

Long Ideas

Markets

Trading Ideas

AMAT

How To Earn $500 A Month From Applied Materials Stock Ahead Of Q2 Earnings

RWE (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RWEOY#OTC">RWEOY</a>) reported quarterly earnings of $0.72 per share. This is a 38.46 percent decrease over earnings of $1.17 per share from the same period last year. The company reported $6.72 billion in sales this quarter. This is a 6.71 percent decrease over sales of $7.20 billion the same period last year.

Rwe Ag Ord Bearer Dm5 American Depository Receipt

RWEOY

RWE Q1 Adj. EPS $0.72 Down From $1.17 YoY, Sales $6.72B Down From $7.20B YoY

Wells Fargo analyst Michael Turrin maintains CoreWeave (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) with a Equal-Weight and raises the price target from $50 to $60.

CRWV

Wells Fargo Maintains Equal-Weight on CoreWeave, Raises Price Target to $60

It has been anything but a quiet month in markets but quiet is exactly what the Easy Income Portfolio has achieved once again.
The tariff and trade noise has caused violent moves in the markets, and we have missed almost all of them
We just wrapped up a pretty interesting stretch for the portfolio. It wasn't a runaway rally, but we had more winners than losers, and some of the higher-yielding names really pulled their weight. Overall, the portfolio did what it's designed to do: deliver steady income while keeping a lid on volatility, even as the market tossed a few curveballs our way.
Here's a breakdown of what happened this past month, what we're holding, and how the whole thing holds up if interest rates start to move in either direction.
<hr class="wp-block-separator has-alpha-channel-opacity" />
Winners, Losers, and Everyone in Between
Let's start with the obvious winner: Dorchester Minerals (Ticker: DMLP). This royalty trust keeps pumping out income, and with oil and natural gas prices creeping higher, the market rewarded it. We're not getting our hands dirty in the oil patch—DMLP just collects checks from other people's wells. That's our kind of energy play.
On the credit side, SRLN (floating-rate loans), HYIN (high-yield bonds), BANX (bank credit), and BIZD (business development companies) all had solid months. Interest rates stayed higher for longer, which helped these credit-heavy positions earn their keep. Even PFFA, our preferred stock ETF, held its ground thanks to active management and a tilt toward higher-coupon names.
TYG, which holds pipeline and energy infrastructure companies, saw a little uptick too. It's not flashy, but it does tend to quietly rise when energy demand picks up.
Meanwhile, a few names were flat or down. REM (mortgage REITs) and MTBA (Simplify MBS ETF) were a little soft, mostly due to interest rate jitters. When rates bounce around, mortgage-related funds feel it first. FAX and XBB, our global and Canadian bond funds, didn't do much—but that's fine. They're there to add stability, not fireworks.
FINS and SPE, which invest in financials and special situations, also had a quiet month. But these kinds of holdings are like option tickets. We don't need them to work every month, just when the time is right.
<hr class="wp-block-separator has-alpha-channel-opacity" />
What Exactly Are We Holding?
This portfolio isn't just a bunch of random tickers thrown together. Everything has a role. Here&#8217;s a quick rundown of what each fund gives us:
<ul class="wp-block-list">
<li>Ticker: MTBA – Mortgage-backed securities (very sensitive to rate changes)</li>
<li>Ticker: FINS – Banks, insurance companies, and financial services</li>
<li>Ticker: SRLN – Floating-rate corporate loans</li>
<li>Ticker: DMLP – Oil and gas royalties (no drilling risk)</li>
<li>Ticker: XBB – Canadian investment-grade bonds</li>
<li>Ticker: PFFA – U.S. preferred stocks</li>
<li>Ticker: BANX – Subordinated debt from smaller banks</li>
<li>Ticker: JRI – Global infrastructure and real estate</li>
<li>Ticker: FAX – Asia-Pacific government and corporate bonds</li>
<li>Ticker: TYG – Energy pipelines and infrastructure</li>
<li>Ticker: CEFS – A basket of discounted closed-end funds</li>
<li>Ticker: BIZD – BDCs, which lend to small and mid-sized companies</li>
<li>Ticker: HYIN – High-yield corporate bonds (excluding financials)</li>
<li>Ticker: SPE – Special opportunities and deeply discounted assets</li>
<li>Ticker: REM – Mortgage REITs (very high income, but high risk)</li>
</ul>
Bottom line: we've got credit, income, energy, real assets, and a little bit of global exposure all working together.
<hr class="wp-block-separator has-alpha-channel-opacity" />
How the Portfolio Holds Together
Now let's talk about how these pieces move in relation to one another. This isn't a portfolio where everything moves in the same direction. In fact, that's the whole point. Some assets—like DMLP and TYG—move with oil prices. Others—like FAX and XBB—move with interest rates. A few—like REM and MTBA—are tied to the mortgage market and how investors feel about housing credit risk.
When we ran the correlation data, we found that a lot of these funds don't really move together. That's exactly what we want. Low correlations mean if one piece gets hit, something else can hold up or even rally. It's like having a group of friends where one's always calm, one's the life of the party, and one always brings snacks. Everyone has a role.
<hr class="wp-block-separator has-alpha-channel-opacity" />
What Happens if Rates Move? We Ran the Numbers
We also stress-tested the portfolio to see how it would react to big moves in interest rates.
If interest rates jump by 1%:
<ul class="wp-block-list">
<li>Bond funds like XBB, FAX, and REM would take a hit—anywhere from 3% to 5%.</li>
<li>PFFA and BANX would probably dip a little too.</li>
<li>But names like DMLP, TYG, and SRLN would likely go up. These types of investments actually benefit when rates rise because they're linked to commodities or float with the market.</li>
</ul>
If rates drop by 1%:
<ul class="wp-block-list">
<li>Bonds bounce back. REM, XBB, and FAX could gain 4% to 5%.</li>
<li>Preferreds like PFFA would catch a tailwind.</li>
<li>Floating-rate loans and energy plays would lag, but we wouldn't expect anything dramatic.</li>
</ul>
The key takeaway? This portfolio has protection on both sides of the rate spectrum. If rates rise, we've got floating-rate credit and oil. If rates fall, we've got bonds and preferreds ready to rally.
<hr class="wp-block-separator has-alpha-channel-opacity" />
The Bottom Line
This portfolio is built to grind out income while avoiding big drawdowns. We're not trying to shoot the lights out, and we're not betting the farm on any single theme. What we are doing is collecting income from multiple sources—credit, energy, real estate, and discounted assets—and letting time and discipline do the work.
If the Fed gets it wrong, we've got hedges. If they pull off a soft landing, we've got plenty of yield. And if volatility keeps creeping in, we're holding assets that don't all move the same way.

Opinion

DMLP

Easy Income Portfolio: May 2025 Update

Wells Fargo analyst Ken Gawrelski maintains Ibotta (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBTA#NYSE">IBTA</a>) with a Overweight and raises the price target from $52 to $60.

IBTA

Wells Fargo Maintains Overweight on Ibotta, Raises Price Target to $60

Mitsubishi UFJ Finl Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUFG#NYSE">MUFG</a>) reported quarterly earnings of $0.07 per share. This is a 36.36 percent decrease over earnings of $0.11 per share from the same period last year. The company reported $22.01 billion in sales this quarter. This is a 3.44 percent decrease over sales of $22.80 billion the same period last year.

MUFG

Mitsubishi UFJ Finl Gr Q4 GAAP EPS $0.07 Down From $0.11 YoY, Sales $22.01B Down From $22.80B YoY

Wells Fargo analyst Andrew Bauch maintains Global E Online (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLBE#NASDAQ">GLBE</a>) with a Overweight and lowers the price target from $45 to $40.

GLBE

Wells Fargo Maintains Overweight on Global E Online, Lowers Price Target to $40

Saudi Arabian Mining Company (Ma'aden) has signed a memorandum of understanding with MP Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MP#NYSE">MP</a>) to develop an integrated rare earth supply chain in Saudi Arabia. The agreement, signed on the sidelines of the <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45390422/trump-unveils-historic-and-transformative-600-billion-saudi-deal-predicts-markets-will-go-a-lot-higher">U.S.-Saudi Investment Forum 2025</a> in Riyadh, reflects both governments' appetites for securing critical mineral supply chains.
Under the agreement, Ma'aden and MP Materials will explore cooperation across the rare earth value chain—from mining and separation to refining and magnet production. Rare earth magnets are essential components in electric vehicles, wind turbines, aerospace systems, and robotics industries, projected to grow exponentially over the next decade.
Ma'aden, which operates 17 mines and exports minerals to 55 countries in 2024, continues to scale its mining sector as part of Saudi Arabia's Vision 2030 economic strategy.
"We aim to create a global hub for a fully integrated rare earth value chain supporting advanced manufacturing in the Kingdom," <a href="https://mpmaterials.com/news/maaden-and-mp-materials-collaborate-to-establish-full-value-chain-for-rare-earth-magnetics">said</a> Ma'aden CEO Bob Wilt. "This is an integral step in the exploration and development of minerals that will drive economic and industrial growth for the Kingdom."
MP Materials, which operates the only commercial-scale rare earth mine and processing facility in the U.S., brings the technical expertise and industrial scale needed to help establish Saudi Arabia as a major player in this field.
"Today's announcement is an important first step towards rebalancing the global supply chain in a moment of transformational growth fueled by emerging technologies—especially in robotics and physical AI," said MP Materials CEO James Litinsky.
The rare earth sector has taken on increasing strategic importance as the U.S. seeks to reduce dependence on China, which accounts for over 60% of production and over 80% of refining capacity. The Biden and Trump administrations have made reshoring and diversifying rare earth supply chains a national security priority.  Although used in relatively small quantities, these minerals are essential for the functionality of many advanced technologies.
In addition to the Ma'aden-MP Materials deal, U.S. and Saudi officials also advanced a $9 billion critical minerals initiative that allows Grand Mines Mining LLC to explore for lithium, cobalt, and rare earths in Saudi Arabia and Africa, with future exports directed to the United States, according <a href="https://www.washingtonpost.com/technology/2025/05/13/trump-mideast-chips-mines-minerals-uae-saudi/">to</a> The Washington Post.
However, the broader implications of these deals, especially those involving advanced AI hardware exports, have drawn criticism. Sam Winter-Levy, a Technology and International Affairs Program fellow at the Carnegie Endowment for International Peace, warned about offshoring American AI and critical minerals know-how to the Middle East.
"We essentially spent the last half-century trying to reduce the leverage of these states over the U.S. because of their control of the oil supply. Why would we recreate that dependency?" he said, pointing at Saudi Arabia&#8217;s close ties with Russia and China.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/guidance/25/05/45402224/short-term-excess-cobalt-supply-masks-long-term-trend-study-says">Short-Term Excess Cobalt Supply Masks Long-Term Trend, Study Says</a></li>
</ul>
Photo: Shutterstock

Government

Large Cap

Commodities

Politics

Legal

Global

US And Saudi Forge Rare Earth Alliance, But Are We Trading One Dependency For Another?

<a href="https://www.ft.com/content/0e12be6a-c1fd-438b-9cd8-49affa33d310" title="https://www.ft.com/content/0e12be6a-c1fd-438b-9cd8-49affa33d310">https://www.ft.com/content/0e12be6a-c1fd-438b-9cd8-49affa33d310</a>

Macro Economic Events

Economics

General

'Trump's Trade War Risks U.S. Capital Flight, Warns Hedge Fund Elliott' - Financial Times

Wells Fargo analyst Sam Reid maintains Owens-Corning (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OC#NYSE">OC</a>) with a Overweight and raises the price target from $150 to $160.

Wells Fargo Maintains Overweight on Owens-Corning, Raises Price Target to $160

Wells Fargo analyst Roger Read maintains Suncor Energy (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SU#TSX">SU</a>) with a Overweight and raises the price target from C$57 to C$59.

TSX:SU

Wells Fargo Maintains Overweight on Suncor Energy, Raises Price Target to C$59

Earnings Misses

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

UPDATE: Chemomab Therapeutics Q1 EPADS $(0.14) Misses $(0.10) Estimate

Stephens &amp; Co. analyst Mason Carrico reiterates 10x Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>) with a Overweight and maintains $14 price target.

Reiteration

Stephens & Co. Reiterates Overweight on 10x Genomics, Maintains $14 Price Target

Stonepeak, a leading alternative investment firm specializing in infrastructure and real assets, and Energy Equation Partners (&quot;EEP&quot;), a newly formed investment firm with significant expertise in fuel retail, today announced an agreement to acquire a majority interest in JET Tankstellen Deutschland GmbH (&quot;JET&quot;), a leading fuel retailer in Germany and Austria, from a subsidiary of Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>), in a transaction valuing the business at an enterprise value of approximately &euro;2.5 billion. Phillips 66 will retain a 35% minority interest in JET as part of the transaction through a newly formed joint venture.

Asset Sales

Stonepeak And Energy Equation Partners To Acquire Majority Interest In JET From Phillips 66 For €2.5B Deal; Phillips 66 To Retain 35% Minority Interest In JET As Part Of Transaction Through Newly Formed JV

Gambling.com Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GAMB#NASDAQ">GAMB</a>) reported quarterly earnings of $0.46 per share which beat the analyst consensus estimate of $0.25 by 84 percent. This is a 130 percent increase over earnings of $0.20 per share from the same period last year. The company reported quarterly sales of $40.63 million which beat the analyst consensus estimate of $40.06 million by 1.42 percent. This is a 39.09 percent increase over sales of $29.21 million the same period last year.

Earnings Beats

GAMB

CORRECTION: Gambling.com Gr Q1 Adj. EPS $0.46 Beats $0.25 Estimate, Sales $40.63M Beat $40.06M Estimate

Wells Fargo analyst Roger Read maintains Canadian Natural Res (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CNQ#TSX">CNQ</a>) with a Equal-Weight and raises the price target from C$40 to C$42.

TSX:CNQ

Wells Fargo Maintains Equal-Weight on Canadian Natural Res, Raises Price Target to C$42

Ideal Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPWR#NASDAQ">IPWR</a>) reported quarterly losses of $(0.30) per share. This is a 23.08 percent increase over losses of $(0.39) per share from the same period last year. The company reported quarterly sales of $12.00 thousand which beat the analyst consensus estimate of $10.00 thousand by 20.03 percent. This is a 84.76 percent decrease over sales of $78.74 thousand the same period last year.

IPWR

Ideal Power Q1 EPS $(0.30) Up From $(0.39) YoY, Sales $12.00K Beat $10.00K Estimate

<a href="https://www.mastercard.com/news/press/2025/may/mastercard-and-moonpay-team-up-to-mainstream-stablecoin-payments/" title="https://www.mastercard.com/news/press/2025/may/mastercard-and-moonpay-team-up-to-mainstream-stablecoin-payments/">https://www.mastercard.com/news/press/2025/may/mastercard-and-moonpay-team-up-to-mainstream-stablecoin-payments/</a>

'Mastercard And MoonPay Team Up To Mainstream Stablecoin Payments' - Newsroom

Press Releases

Roivant Reports Financial Results for the Second Quarter Ended September 30, 2024, and Provides Business Update

Roivant Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis

Kinevant Sciences Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis

Roivant to Report Financial Results for the Third Quarter Ended December 31, 2024 and Provide Business Update on Monday, February 10, 2025

Health Care

Zest Health Announces $13M in Funding to Curb Unnecessary Pharmaceutical Spend through High-Touch Care

Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402

Comments

Roivant Sciences

空売り

Roivant Sciences (NASDAQ:ROIV) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル